MdxHealth (TM) : MDxHealth and Sumitomo Sign Pharmaco Molecular Diagnostic Partnership for Japan

  MdxHealth (TM) : MDxHealth and Sumitomo Sign Pharmaco Molecular Diagnostic
                            Partnership for Japan

IRVINE, CA, and LIEGE, BELGIUM  - 8:00 AM, July 1,  2013 - MDxHealth SA  (NYSE 
Euronext: MDXH),  a leading  molecular diagnostic  company that  develops  and 
commercializes epigenetic  tests to  support the  diagnosis and  treatment  of 
cancer patients,  today announced  the signing  of a  partnership with  Summit 
Pharmaceuticals International  Corporation  (SPI)  a  subsidiary  of  Sumitomo 
Corporation to gain access to the Japanese market with its pharmaco  molecular 
diagnostic (PharmacoMDx) epigenetic technologies and products. Expanding  upon 
MDxHealth's PharmacoMDx  program, the  partnership aims  to provide  companion 
diagnostic solutions,  or theranostics,  to  pharmaceutical companies  in  the 
Japanese market. No financial terms have been disclosed.

"As the  global life  sciences  industry continues  to pair  diagnostics  with 
therapeutics to determine patient response,  we believe this partnership  with 
SPI will  provide  MDxHealth with  the  necessary leverage  and  expertise  to 
penetrate the Japanese market,"  stated Dr. Jan Groen,  CEO of MDxHealth.  "We 
look forward  to  working  closely with  the  SPI  team to  offer  our  unique 
epigenetic PharmacoMDx products and services to drug development companies."

MDxHealth's PharmacoMDx  team leverages  Next-Generation and  Deep  Sequencing 
technologies for  the identification  and  validation of  powerful  epigenetic 
biomarkers for novel therapeutics. Companion diagnostic assays are playing an
increasingly important role  in the  development process of  new compounds  as 
they can help  identify patients who  may benefit from  a new drug,  improving 
efficacy,  reducing  adverse  side   effects,  and  potentially   accelerating 
regulatory approval thereby helping pharma companies reduce the time and  cost 
associated with bringing new products to market. 

About Summit Pharmaceuticals International Corporation
Summit Pharmaceuticals International Corporation is a group of specialists  in 
Japan that  provides  high-quality  integrated services  from  drug  discovery 
research to the production stage of  pharmaceuticals and chemicals. SPI is  a 
subsidiary of Sumitomo Corporation which is a leading general trading  company 
with 140 locations in 66 countries throughout the world. For more information,
visit http://www.summitpharma.co.jp/.

About MDxHealth^®
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of  patients.  The  company's  first  commercial  product,  ConfirmMDx^TM  for 
Prostate Cancer,  has been  shown  to help  distinguish  patients who  have  a 
true-negative biopsy  from those  who may  have undetected  cancer.  MDxHealth 
helps to address  a large  and growing unmet  medical need  for better  cancer 
diagnosis and treatment  information. The company  has a proprietary  platform 
and a  strong  epigenetic  product  pipeline focused  on  the  development  of 
products for prostate, brain and lung cancers. The company is based in Irvine,
California  with  a  European  headquarters   in  Liege,  Belgium.  For   more 
information visit MDxHealth's website at www.mdxhealth.com.

For more information: Mike Sinclair          Seth Lewis
Dr. Jan Groen, CEO    Halsin Partners        The Trout Group
MDxHealth             UK: +44 20 7318 2955
US: +1 949 812 6979   Cell: +44 7968 022075  US: +1 646 378 2952
BE: +32 4 364 20 70   msinclair@halsin.com  slewis@troutgroup.com 
info@mdxhealth.com 

This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless  required by  law or  regulation. This  press release  does  not 
constitute an offer or  invitation for the sale  or purchase of securities  or 
assets of MDxHealth  in any jurisdiction.  No securities of  MDxHealth may  be 
offered or sold within the United  States without registration under the  U.S. 
Securities Act  of  1933, as  amended,  or  in compliance  with  an  exemption 
therefrom, and in accordance with any applicable U.S. securities laws.



NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are  trademarks 
or registered trademarks  of MDxHealth  SA. All other  trademarks and  service 
marks are the property of their respective owners.

To access the PDF version, please click here

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MdxHealth (TM) via Thomson Reuters ONE
HUG#1712764